Gilder Gagnon Howe & Co. LLC lowered its stake in Sientra, Inc. (NASDAQ:SIEN) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,091,626 shares of the medical instruments supplier’s stock after selling 22,885 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned 5.65% of Sientra worth $16,811,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in SIEN. Bamco Inc. NY increased its stake in shares of Sientra by 109.3% in the 2nd quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock valued at $4,583,000 after acquiring an additional 246,183 shares in the last quarter. State Street Corp bought a new stake in shares of Sientra in the 2nd quarter valued at $1,449,000. Northern Trust Corp increased its stake in shares of Sientra by 449.4% in the 2nd quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock valued at $1,451,000 after acquiring an additional 122,066 shares in the last quarter. Cloverdale Capital Management LLC increased its stake in shares of Sientra by 28.9% in the 2nd quarter. Cloverdale Capital Management LLC now owns 492,237 shares of the medical instruments supplier’s stock valued at $4,785,000 after acquiring an additional 110,495 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of Sientra by 449.6% in the 1st quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock valued at $1,081,000 after acquiring an additional 105,005 shares in the last quarter. Institutional investors own 76.99% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Sientra, Inc. (SIEN) Shares Sold by Gilder Gagnon Howe & Co. LLC” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/11/14/sientra-inc-sien-shares-sold-by-gilder-gagnon-howe-co-llc.html.
Shares of Sientra, Inc. (SIEN) traded up $0.37 during mid-day trading on Tuesday, reaching $13.87. 85,500 shares of the company’s stock were exchanged, compared to its average volume of 156,383. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92. Sientra, Inc. has a fifty-two week low of $7.20 and a fifty-two week high of $16.68.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.06). The business had revenue of $9.80 million for the quarter, compared to the consensus estimate of $10.54 million. Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The business’s revenue for the quarter was up 50.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.55) EPS. analysts forecast that Sientra, Inc. will post -3.14 EPS for the current year.
Several research firms have recently weighed in on SIEN. Lake Street Capital reiterated a “buy” rating and issued a $15.00 price objective (up previously from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Stifel Nicolaus restated a “hold” rating and set a $14.00 price target (up previously from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. Zacks Investment Research lowered shares of Sientra from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. Canaccord Genuity restated a “buy” rating and set a $14.00 price target on shares of Sientra in a research note on Sunday, October 8th. Finally, William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $13.75.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.